玻璃体腔注射康柏西普联合全视网膜光凝术治疗糖尿病性黄斑水肿的临床研究  

Clinical Study on Intravitreal Injection of Conbercept Combined with Panretinal Photocoagulation in the Treatment of Diabetic Macular Edema

作　　者：王健[1] 杨华鹏[1] 崔瑞[1] WANG Jian;YANG Huapeng;CUI Rui(Department of Ophthalmology,Luohe Third People's Hospital/Luohe Maternal and Child Health Hospital,Luohe 462000,China)

机构地区：[1]漯河市第三人民医院/漯河市妇幼保健院眼科,河南漯河462000

出　　处：《临床医学工程》2024年第9期1039-1040,共2页Clinical Medicine & Engineering

摘　　要：目的探讨玻璃体腔注射康柏西普联合全视网膜光凝术(PRP)治疗糖尿病性黄斑水肿(DME)的效果。方法将我院收治的DME患者160例随机分为参照组(n=80)和研究组(n=80)。参照组予以PRP治疗,研究组予以玻璃体腔注射康柏西普联合PRP治疗。比较两组的BCVA、CMT、眼压、术后并发症发生情况。结果术后1个月,两组的BCVA均高于术前,CMT、眼压低于术前(P<0.05);研究组BCVA高于参照组,CMT、眼压低于参照组(P<0.05)。研究组术后并发症发生率为1.25%,低于参照组的10.00%(P<0.05)。结论玻璃体腔注射康柏西普联合PRP治疗可明显改善DME患者的BCVA,降低黄斑区CMT,调节眼压水平,且并发症较少。Objective To explore the effect of intravitreal injection of conbercept combined with panretinal photocoagulation(PRP)in the treatment of diabetic macular edema(DME).Methods 160 DME patients admitted to our hospital were randomly divided into reference group(n=80)and study group(n=80).The reference group was treated with PRP,and the study group was treated with intravitreal injection of conbercept combined with PRP.The BCVA,CMT,intraocular pressure and postoperative complications were compared between the two groups.Results 1 month after surgery,the BCVA of the two groups were higher than those before surgery,and the CMT and intraocular pressure were lower than those before surgery(P<0.05);The BCVA of the study group was higher than that of the control group,and the CMT and intraocular pressure were lower than those of the control group(P<0.05).The incidence of postoperative complications in the study group was 1.25%,lower than 10.00%in the reference group(P<0.05).Conclusions Intravitreal injection of conbercept combined with PRP can significantly improve the BCVA of DME patients,reduce the CMT of macular area,and regulate the intraocular pressure level,with fewer complications.

关 键 词：糖尿病性黄斑水肿 全视网膜光凝术 康柏西普 最佳矫正视力 

分 类 号：R587.2[医药卫生—内分泌]